The Lancet Commission on Prostate Cancer is an initiative by The Lancet, one of the world’s leading medical journals, aimed at addressing the complex issues surrounding prostate cancer through a comprehensive and in-depth report.

Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. This Commission reports on projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy. Their findings suggest that the number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040.

Read the article here. Or watch the webcast of their presentation at EAU24

Cancerworld reports on a study, published in JAMA Network Open, which found that men diagnosed with early-stage prostate cancer who had a high intake of plant-based foods had a 47% lower risk of progression.

Our Vice Chairman, Erik Briers, commented in the article that dietary advice given to European prostate cancer patients is mostly down to the personal initiative of the urologist or nurse specialist.

You can read the article here.

At the Europa Uomo AGM 2024, the Board of Europa Uomo changed.

Cosimo Pieri (Italy) has decided not to stand up for a second term and leaves the Board. Erik Briers (Belgium) and Tania Estapé (Spain) were both elected for a second three-year term. Kees Vos (Netherlands) was elected for a first term on the Board.

The new Board 2024-2025 is:
Chairman: Ernst-Günther Carl (Germany)
Secretary: Steven Lerys (France)
Treasurer: Ioannis Vanezos (Cyprus)
Vice Chairman: Erik Briers (Belgium)
Vice Chairman: Nils Petter Sjøholt (Norway)
Board member: Marko Koivuneva (Finland)
Board member: Tania Estapé (Spain)
Board member: Paulius Rakstys (Lithuania)
Board member: Kees Vos (Netherlands)

Ex-Officio members:
André Deschamps (Belgium, Past-chairman – advisor to the Board)
Alberto Costa (Switzerland/Italy, ESO)
Simon Crompton (UK, Communication advisor)
Hein Van Poppel (Belgium, EAU)

The Europa Uomo chatbot is now available on our website. You can access it by clicking on the dialogue box at the bottom right of every page.

The chatbot, available in 98 languages, is based on the EAU guidelines on prostate cancer and gives scientifically substantiated answers to questions about prostate cancer. However, it does not replace a consultation with a specialist.

Please try out the chatbot, and let us know what you think. info@europa-uomo.org

The Europa Uomo Summer School is a one-week training programme to help Europa Uomo members become expert patient advocates. The sessions will be run by a high-level panel of prostate cancer experts in the field, and experienced patient advocates.

The event is being held in Brussels, Belgium on 1st-6th September 2024.

Each Europa Uomo member organisation should identify up to two candidates via the registration page. The Europa Uomo Board will then consider applications, select appropriate candidates to attend and inform them of their registration.

More information here.

After a successful General Assembly meeting in Milan, the Europa Uomo Annual Report 2023/24 is available here.

PatientView, a UK-based research, publishing, and consultancy group, has surveyed patient groups about their attitudes to the pharmaceutical industry. The latest global publication, gives a view on how patient organisations are viewing the performance of both the industry and individual pharma companies. Europa Uomo has been taking part in these surveys.

You can read the Patient Summary of “The Corporate Reputation of Pharma, 2023: How patient-group perceptions of pharma are evolving rapidly” here.